Compare OMCL & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OMCL | INVA |
|---|---|---|
| Founded | 1992 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2001 | 2004 |
| Metric | OMCL | INVA |
|---|---|---|
| Price | $43.26 | $20.19 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $43.00 | $36.60 |
| AVG Volume (30 Days) | 511.1K | ★ 789.4K |
| Earning Date | 10-30-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.96 |
| EPS | 0.43 | ★ 1.52 |
| Revenue | ★ $1,177,740,000.00 | $388,521,000.00 |
| Revenue This Year | $8.61 | $13.23 |
| Revenue Next Year | $3.97 | $8.62 |
| P/E Ratio | $103.10 | ★ $13.53 |
| Revenue Growth | ★ 10.67 | 10.14 |
| 52 Week Low | $22.66 | $16.52 |
| 52 Week High | $47.69 | $22.76 |
| Indicator | OMCL | INVA |
|---|---|---|
| Relative Strength Index (RSI) | 70.82 | 42.95 |
| Support Level | $39.18 | $20.44 |
| Resistance Level | $45.36 | $21.00 |
| Average True Range (ATR) | 1.95 | 0.56 |
| MACD | 0.41 | -0.21 |
| Stochastic Oscillator | 80.11 | 5.29 |
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.